Aarti Pharmalabs DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.81×	0.78×	0.76×	0.72×	0.74×
	0.86×	0.85×	0.96×	0.96×	0.93×
	17.1%	14.6%	17.8%	16.9%	14.4%
	0.57×	0.57×	0.77×	0.77×	0.91×
	1.70×	1.64×	1.46×	1.47×	1.43×
	11.5%	9.0%	14.5%	13.2%	13.0%
	8.4%	8.4%	14.5%	13.1%	13.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AARTIPHARM₹823.65

Aarti Pharmalabs Ltd.

· Pharma & Health

₹ CrorePeersAARTIDRUGS ADVENZYMES AGARWALEYE AKUMS ALIVUS APLLTD CORONA HCGMcap ₹7,467 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.74	0.72	0.76	0.78	0.81
Interest Burden (Pretax/EBIT) ×	0.93	0.96	0.96	0.85	0.86
EBIT Margin %	14.37	16.88	17.85	14.56	17.09
Asset Turnover ×	0.91	0.77	0.77	0.57	0.57
Financial Leverage (Assets/Equity) ×	1.43	1.47	1.46	1.64	1.70
ROE (5-step product, year-end total equity) %	12.96	13.25	14.48	8.97	11.49
ROE (owners' profit / average owners' equity) %	13.14	13.06	14.54	8.40	8.40

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.